Literature DB >> 29153859

Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

F McDonald1, G G Hanna2.   

Abstract

Entities:  

Year:  2017        PMID： 29153859     DOI： 10.1016/j.clon.2017.10.013

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  7 in total

1.  Local consolidative therapy for oligometastatic non-small cell lung cancer.

Authors:  Pamela P Samson; Matthew B Spraker; Shahed N Badiyan; Gregory Vlacich; Clifford G Robinson; Aadel A Chaudhuri
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

2.  Randomized phase II trial reporting overall survival advantage by adding local consolidative therapy to systemic therapy for oligometastatic non-small cell lung cancer: another step forward on the long road of evidence-based medicine for oligometastatic disease.

Authors:  Paul Windisch; Matthias Guckenberger
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.

Authors:  Giulio Metro; Alfredo Addeo; Diego Signorelli; Alessio Gili; Panagiota Economopoulou; Fausto Roila; Giuseppe Banna; Alessandro De Toma; Juliana Rey Cobo; Andrea Camerini; Athina Christopoulou; Giuseppe Lo Russo; Marco Banini; Domenico Galetta; Beatriz Jimenez; Ana Collazo-Lorduy; Antonio Calles; Panagiotis Baxevanos; Helena Linardou; Paris Kosmidis; Marina C Garassino; Giannis Mountzios
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

4.  Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).

Authors:  Reem Alomran; Michelle White; Melissa Bruce; Mathias Bressel; Susan Roache; Lama Karroum; Gerard G Hanna; Shankar Siva; Shom Goel; Steven David
Journal:  BMC Cancer       Date:  2021-03-23       Impact factor: 4.430

Review 5.  Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature.

Authors:  Maria Walls; Gerard M Walls; Jacqueline A James; Kyle T Crawford; Hossam Abdulkhalek; Tom B Lynch; Aaron J Peace; Terry E McManus; O Rhun Evans
Journal:  BMC Pulm Med       Date:  2020-08-06       Impact factor: 3.317

Review 6.  Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham's (UK) Experience.

Authors:  Sundus Yahya; Qamar Ghafoor; Robert Stevenson; Steven Watkins; Beshar Allos
Journal:  Medicines (Basel)       Date:  2018-07-23

7.  Current status of stereotactic ablative body radiotherapy in the UK: six years of progress.

Authors:  Gail Distefano; Satya Garikipati; Helen Grimes; Matthew Hatton
Journal:  BJR Open       Date:  2019-07-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.